A plain-language guide

Paroxysmal nocturnal hemoglobinuria

What is known, what is still uncertain, and what is actively debated, written plainly, and built only from published medical research.

Early map · 11 sourced statements Every statement names its source Updated 2026-06-11
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. Paroxysmal nocturnal hemoglobinuria is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What it is

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder in which a faulty group of blood cells lets the body's complement system destroy red blood cells from inside the bloodstream, causing anemia, a risk of dangerous blood clots, and dark urine.

Signs and symptoms

Anemia

Anemia, a shortage of healthy red blood cells, is a common feature of PNH and can cause fatigue and shortness of breath.

Limited evidenceSource: ORPHA:447
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41171226
Notesplain_language confirmed from PMID:41171226 via curation 2026-06-11.
Last reviewed2026-06-11

Hemolytic anemia

In PNH, red blood cells are broken apart inside the bloodstream, a process called hemolytic anemia, which lowers the blood's ability to carry oxygen.

Limited evidenceSource: ORPHA:447
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:25237200
Notesplain_language confirmed from PMID:25237200 via curation 2026-06-11.
Last reviewed2026-06-11

Thromboembolism

People with PNH have a high risk of thromboembolism (blood clots that block vessels), which is a leading cause of serious illness and death in the disease.

Limited evidenceSource: ORPHA:447
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:30185704
Notesplain_language confirmed from PMID:30185704 via curation 2026-06-11.
Last reviewed2026-06-11

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

Ravulizumab

Ravulizumab is a long-acting medicine given by infusion that blocks the complement protein C5, reducing the destruction of red blood cells in PNH.

Used to help with: Paroxysmal nocturnal hemoglobinuria.

Limited evidenceSource: PMID:39841198
The source text this rests on
“Ravulizumab is a second-generation complement component 5 (C5) inhibitor (C5i) approved for the treatment of paroxysmal nocturnal hemoglobinuria…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:39841198 via curation 2026-06-11
Last reviewed2026-06-11

Eculizumab

Eculizumab is an antibody medicine that blocks the complement protein C5, reducing the complement-driven destruction of red blood cells in PNH.

Used to help with: Paroxysmal nocturnal hemoglobinuria.

Limited evidenceSource: PMID:25237200
The source text this rests on
“Eculizumab, a first-in-class monoclonal antibody that inhibits terminal complement, is the treatment of choice for patients with severe manifestations of PNH.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:30185704
Notesconfirmed from PMID:25237200 via curation 2026-06-11
Last reviewed2026-06-11

Turn this into questions for your doctor

The hardest part is often knowing what to ask. PatientLead Health helps families turn what is on this page into the right questions for their care team.

Prepare for your appointment with PatientLead Health →

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.

Where this comes from

This guide is built from 4 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

ORPHA:447 · Orphanet/HPO annotations for Paroxysmal nocturnal hemoglobinuria
PMID:25237200 · Paroxysmal nocturnal hemoglobinuria.
PMID:30185704 · Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab.
PMID:39841198 · Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal